建设内容：在本公司"微元合成绿色生物制造二期项目"车间内，建设"微元合成绿色生物制造二期健 康糖项目"，利用现有发酵、公用工程和检验等设备，新增膜分离、离交、浓缩、结晶、分离干燥等 设备， 项目建成后， 柔性生产阿洛酮糖和甘露糖醇（食品级）， 年产量共计2000吨 。 阿洛酮糖 作为一种新型低倍甜味剂，具备多种生理功效，如抑制人体对糖类的吸收、降血糖、抗氧 化等，是蔗糖的理想替代品。 甘露糖醇 则广泛应用于医药、食品、化工等领域，作为甜味剂、保湿 剂、赋形剂等。 2、在建项目 "微元合成绿色生物制造二期项目"，项目运用生物提取技术，以一水合葡萄糖、柠檬酸、磷酸二氢 钾、硫酸钾等组分组成的培养液为基本原料，利用菌体进行发酵得到产物胆红素后进行纯化提取，从 而制出胆红素产品。目前项目正在建设过程中，建成后年生产胆红素5吨。 3、微元合成 【SynBioCon】 获悉，近日，关于 微元合成生物技术（秦皇岛）有限公司 微元合成绿色生物制造 二期健康糖项目在相关网站批复前公示。 1、项目基本情况 项目名称：微元合成绿色生物制造二期健康糖项目 建设单位：微元合成生物技术（秦皇岛）有限公司 项目投资：4000万元 微元合成 ...

Core Viewpoint - The company has received four medical device registration certificates from the National Medical Products Administration and the Guangdong Provincial Medical Products Administration for various diagnostic test kits [1] Group 1 - The company obtained registration for the Hepatitis E Virus IgM Antibody Test Kit (Magnetic Microparticle Chemiluminescence Method) [1] - The company received approval for the Hepatitis E Virus IgG Antibody Test Kit (Magnetic Microparticle Chemiluminescence Method) [1] - The company has been granted a registration certificate for the Zinc Determination Test Kit (PAPS Colorimetric Method) [1] - The company also received a registration certificate for the Direct Bilirubin Determination Test Kit (Heavy Nitrogen Salt Method) [1]

Core Viewpoint - The financial performance of Jianfan Biological shows a strong growth in 2024, but a significant decline in Q1 2025 raises concerns about the sustainability of its pricing strategy and reliance on a single product line [1][2]. Financial Performance - In 2024, Jianfan Biological achieved a revenue of 2.677 billion yuan, a year-on-year increase of 39.27%, and a net profit of 820 million yuan, up 87.91% [1]. - The first quarter of 2025 saw a revenue drop to 548 million yuan, a decline of 26.40%, and a net profit decrease to 189 million yuan, down 33.71% [1]. Product and Market Dynamics - The blood purification market shows strong demand, with Jianfan's blood perfusion devices generating 2.504 billion yuan in sales in 2024, a 59.58% increase, accounting for 93.6% of total revenue [3]. - The company has initiated a price reduction strategy, lowering the price of its main product by 26%, which led to a significant increase in sales volume [3][4]. Business Structure and Risks - Jianfan Biological's heavy reliance on blood perfusion devices poses risks, as changes in policy, technology, or market demand could impact operations [4]. - The company is transitioning from a single-product dependency to a diversified product portfolio, including differentiated products in the nephrology field and new growth areas in hepatology and critical care [5]. International Expansion - Jianfan has made strides in international markets, obtaining product approvals in 98 countries, with overseas revenue reaching 59.36 million yuan, representing only 2.2% of total revenue [6]. - The company faces challenges in overcoming technical recognition differences and certification barriers in foreign markets [6]. Competitive Landscape - The potential inclusion of blood perfusion products in centralized procurement could pressure prices, although the company believes that quality and technological leadership will be considered in future procurement policies [7]. - The competitive environment is intensifying, with over 14 domestic companies and international giants entering the blood perfusion market, challenging Jianfan's market share [7]. Future Outlook - For 2025, Jianfan plans to focus on deepening its presence in the domestic blood purification market while expanding internationally, particularly in liver disease and critical care markets [8]. - The company aims to explore new applications for blood perfusion technology in sub-health areas and seek quality acquisition targets through capital market tools [8].

报名：首届全球眼科大会 | 参会须知 报名：首届全球骨科大会 | 议程更新 报名：首届全球心血管大会 | 奖项申报 合作伙伴征集：2025全球手术机器人大会 2025年4月16日， 健帆生物 发布了2024年年报。 # 财报数据 健帆生物2024年实现营业 收入26.77亿元 ，同比 增长39.27% 。归属于上市公司股东的净利润为8.20亿元，同比 增长87.91% 。扣除非经常性损益的净利润为 7.79亿元，同比 增长90.46% 。 业务核心驱动力 分红政策 公司2024年度权益分配预案为每10股派发现金红利8元（含税），合计派发现金红利6.19亿元，占净利润的比例为 75.53% 。 每股收益 ：基本每股收益为1.05元，同比 增长90.91% 。 经营活动现金流 ：经营活动产生的现金流量净额为10.51亿元，同比增长14.64%。 资产总额 ：截至2024年末，公司资产总额为53.83亿元，较上年末下降2.88%。 产品销售增长 ：公司血液灌流器及吸附器产品销售收入达到25.04亿元，同比增长59.58%，是推动营收增长的主要因素。 市场拓展与新产品推广 ：公司在肾病、肝病和危重症领域持续巩固市场领 ...